The Lynx Group
Cholangiocarcinoma News

Monthly Minutes

Web Exclusives — December 20, 2021
Infigratinib demonstrates significant efficacy and a manageable safety profile in patients with previously treated, locally advanced or metastatic CCA with an FGFR2 gene fusion or rearrangement.
Read More

Web Exclusives — December 20, 2021
The ClarIDHy trial demonstrated safety and efficacy of ivosidenib in patients with previously treated metastatic CCA harboring an IDH1 mutation.
Read More

Web Exclusives — December 20, 2021
Initial results of the phase 2 FOENIX-CCA2 study demonstrated that futibatinib demonstrated efficacy and a manageable safety profile in patients with previously treated iCCA harboring an FGFR2 fusion or rearrangement.
Read More

Web Exclusives — December 20, 2021
The phase 2 FIDES-01 study demonstrated that derazantinib resulted in objective responses and a manageable safety profile in patients with previously treated iCCA with an FGFR2 fusion or rearrangement.
Read More

Web Exclusives — December 20, 2021
Results from a phase 1 study showed that the bispecific HER2-targeted antibody zanidatamab is well-tolerated and demonstrates clinical activity in patients with HER2-overexpressing biliary tract cancer.
Read More

Web Exclusives — December 20, 2021
The NIFE study demonstrated the efficacy and safety of the nal-IRI-plus-5-FU/LV regimen as first-line therapy in patients with advanced biliary tract cancer, with a clear benefit over gemcitabine/cisplatin in extrahepatic cholangiocarcinoma.
Read More

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: